News | May 14, 2025
Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
RPG Life Sciences has reported total income of Rs. 148.15 crores during the period ended March 31, 2025
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Introduces revolutionary approach to workflow management to enhance operational efficiency and optimize process efficiency
Increases Siemens’ industrial software total addressable market by $11 billion; aligns with strategic goal to accelerate customer innovation across industries
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Subscribe To Our Newsletter & Stay Updated
